14 results about "Dry-powder inhaler" patented technology

The present invention provides a dry powder inhaler comprising one or more containers of powdered medication for inhalation; an outlet through which a user may inhale a dose of medication; and an airway comprising a cyclone chamber The cyclone chamber has a tangential powder inlet channel for supplying the powdered medication from at least one of the one or more dose containers; one or more tangential bypass inlet channels; and an axial exit opening connected to the outlet. When a user inhales on the outlet to create an air flow, medication is entrained in the air flow and flows through the airway via the cyclone chamber, and out through the outlet. The invention is characterized in that the airway comprises a grate between the dose container and the powder inlet channel that prevents large agglomerates of powder from entering the powder inlet channel.

This invention relates to the field of filling equipment technology and discloses a storage-type automated filling equipment for dry powder inhalers. The equipment includes a workbench, a frame fixedly mounted on the top of the workbench, a mounting frame mounted on the top of the frame, a support frame fixedly mounted on the top of the mounting frame, and a drive motor mounted on the top of the support frame. The output shaft of the drive motor passes through the interior of the mounting frame and is fitted with a track. A rotating rod is rotatably mounted inside the mounting frame, and the bottom of the rotating rod passes through the interior of the mounting frame and is fixedly fitted with a rotating wheel. In this invention, a camera, a rotating wheel, a positioning wheel, a drive motor, and an electric push rod work together. The electric push rod pushes the positioning wheel to clamp the filling bottle, the drive motor drives the rotating wheel to rotate and adjust the bottle angle, and the camera identifies and positions the bottle in real time, accurately correcting the bottle placement to ensure precise alignment between the filling nozzle and the discharge port of the filling component.

The invention provides a unit dose dispenser in the form of a blister containing a dry powder for inhalation. The blister comprises a base material in which a cavity is formed comprising a bowl that contains the powder and a channel that opens into the bowl. The channel contains a tube that has separate sections that provide an air outlet and an air inlet. The air outlet is further from the bowl than the air inlet. The upper side of the tube is flat and level with the top of the channel A lid material, such as a foil or foil laminate, seals the cavity. The blister has a detachable portion which, when removed, exposes the air inlet and the air outlet. A process for making the unit dose dispensers is also provided, which is based on the conventional process for manufacturing blister strips for dry powder inhalers.

This disclosure provides a dry powder composition of treprostol prodrug and a method of treating pulmonary hypertension (e.g., pulmonary arterial hypertension or PH associated with interstitial lung disease) in patients in need using said dry powder composition. The dry powder composition comprises: (a) about 0.5 wt% to about 5 wt% of a compound, its stereoisomers, or a pharmaceutically acceptable salt thereof; (b) about 10 wt% to about 61 wt% of leucine; and the remainder is (c) a sugar selected from the group consisting of trehalose and mannitol. The total of (a), (b), and (c) is 100 wt%, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecanyl, or octadecyl. The method of treating PH comprises administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler during an administration period.

Dry powder inhalers and methods of manufacturing the same are described. A dry powder inhaler includes a desiccant containing desiccant beads and a protective layer to maintain efficacy of the desiccant beads, an overcap formed to integrally hold the desiccant, a medicant dispensing component containing a dry powder medicant, and where one of the protective layer and the medicant dispensing component includes a piercing mechanism. Attachment of the overcap to the medicant dispensing component causes the piercing mechanism to tear the protective layer and place the desiccant beads in dry powder communication with the dry powder medicant, enabling the desiccant beads to absorb moisture present in the dry powder inhaler.

There is described herein a dry powder inhaler device (100) for administering a powder by inhalation, comprising: a storage chamber operable to hold a supply of powder; a dosing unit (235) adjacent the storage chamber, the dosing unit comprising a rotatable disc with one or more dosing stations, each dosing station comprising less than 5 dosing holes (250) through the rotatable disc, each dosing hole configured to receive and transfer a metered dose of the powder from the storage chamber to an inhalation channel, wherein each of the dosing holes has a side wall profile comprising a curved section; a pressure plate (240) urged against the dosing unit; and an inhalation channel in fluid communication with the dosing unit, wherein the inhalation channel directs the powder entrained in airflow to a user upon inhalation.

This invention relates to a nucleic acid-lipid nanoparticle dry powder inhaler, its preparation method, and its application. The inhaler comprises a lyophilized nucleic acid-lipid nanoparticle powder and a powder carrier. The lyophilized nucleic acid-lipid nanoparticle powder includes nucleic acids, lipids, buffer salts, and excipients. The lipids include cationic lipids, neutral lipids, auxiliary lipids, and conjugated lipids. The nucleic acid nanoparticles in the inhaler provided by this invention have a particle size controlled at 115 nm, an encapsulation efficiency of over 90%, nucleic acid integrity of over 80%, a median aerodynamic particle size of 2.53 μm, an effective site deposition rate of over 60%, high cell transfection efficiency, and a simple preparation method suitable for industrial production.

A pressurised metered dose inhaler 200, an active dry powder inhaler, a soft mist inhaler or a nebuliser comprising a device 20 comprising canister walls 23 and an end face 24. The inhaler comprises a

This document describes an interactive device and methods for detecting and measuring characteristic patterns in real time of a subject's use of a dry powder inhaler. The inhaler device can be used in wireless communication mode with a display to assess the subject's use of the inhalation system during inhalation, allowing for the evaluation of both the subject's inhalation technique and the system's performance. The system can also detect the drug's identity, dosage, batch number, expiration date, etc., and the characteristic profile of the dry powder formulation emitted by the inhaler in use, enabling the efficient administration of powder doses. The data obtained can be transmitted to a digital application and analyzed to optimize its therapeutic utility.

This invention relates to a dry powder inhaler, comprising: an indexing mechanism including a driving indexing gear and a driven indexing gear, the driving indexing gear including a pawl, and the driven indexing gear including an indexing groove and a guide structure; a peeling mechanism; a counting driving tooth that rotates in response to the rotation of the driven indexing gear; and a counting mechanism having a counting driven tooth and a stop. When the number of uses has not reached a preset threshold, the pawl remains engaged with the indexing groove, and the counting driving tooth remains engaged with the counting driven tooth. When the number of uses reaches the preset threshold, the stop prevents the counting driving tooth from continuing to rotate. When the external force driving the indexing mechanism to rotate exceeds a preset force value, the pawl deforms along the groove opening towards the indexing groove under the guidance of the guide structure, thereby disengaging from the indexing groove. The dry powder inhaler of this invention, when the number of uses reaches the preset threshold, can limit further use of the dry powder inhaler by the user.

The present invention relates to a method to prepare golf ball like microparticles by spray drying of nanosuspensions of nanoparticles or solutions for dry powder inhalers for use in the treatment and prevention of pulmonary diseases.

This invention discloses a capsule-type dry powder inhaler and its working method, comprising: a fixing module, a rotating module, and a top cover; the fixing module has a blind-hole circular cavity with the open end located at the top of the fixing module; the rotating module is disposed in the circular cavity, and a gap is provided between the rotating module and the fixing module; the top cover is installed on the top of the fixing module; a mesh is provided at one end of the mouthpiece of the top cover; a magnet is provided at the bottom of the fixing module, and a magnet is provided at the bottom of the rotating module, and the magnets of the fixing module and the rotating module are attracted by magnetic force; the rotating module also has a capsule chamber, and the capsule chamber has slits at both ends; a puncture device is provided on the fixing module at positions corresponding to the two ends of the capsule chamber. This invention not only solves the problem of easy jamming during capsule rotation in existing dry powder inhalers, but also solves the problems of powder waste and inaccurate dosage caused by low inhalation flow rate.

This invention discloses a method for preparing a bumetanide nasal administration formulation and its application in the treatment of epilepsy, belonging to the field of pharmaceutical technology. The nasal administration formulation is a bumetanide nasal spray and / or a bumetanide dry powder inhaler. The drug is used for immediate administration intervention within 30 minutes after an epileptic seizure in non-medical settings, including at home, outdoors, or during transport. In this invention, the bumetanide nasal spray or dry powder inhaler does not require intravenous puncture or operation by professional medical personnel. Patients or their families can administer the drug directly through the nasal cavity within 30 minutes after an epileptic seizure at home, outdoors, or during transport, breaking through the dependence of traditional intravenous injection on medical settings and equipment, and buying valuable time for neuronal resuscitation.

A dry powder inhaler and an adherence and / or compliance monitor for use with the inhaler are provided. The inhaler has a cover which is pivotable relative to its housing in order to expose a mouthpiece. The monitor has one or more sensors. The inhaler and the monitor have formations for mounting the monitor onto the inhaler. The inhaler and monitor are designed so that when the monitor is mounted onto the housing of the inhaler and the cover is opened, the cover at least partially covers and protects the monitor.